MetaADEDB 2.0 @ LMMD
Clorazepate Dipotassium
(QCHSEDTUUKDTIG-UHFFFAOYSA-L)
Structure
SMILES
[O-]C(=O)C1N=C(c2ccccc2)c2c(NC1=O)ccc(c2)Cl.[K+].[K+].[OH-]
Molecular Formula:
C16H11ClK2N2O4
Molecular Weight:
408.919
Log P:
0.6448
Hydrogen Bond Acceptor:
6
Hydrogen Bond Donor:
2
TPSA:
104.65
CAS Number(s):
57109-90-7
Synonym(s)
1.
Clorazepate Dipotassium
2.
Chlorazepate
3.
Dipotassium Chlorazepate
4.
4306-CB
5.
Clorazepate
6.
Clorazepate Monopotassium
7.
Clorazepic Acid
8.
Tranxene
9.
Tranxilium
External Link(s)
MeSHD003009
PubChem Compound138400065
167305
23706210
5281076
ChEBI3762
CHEMBLCHEMBL2096631
KEGGdr:D00694
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 8US FAERS
2DizzinessFAERS: 6US FAERS
3AnxietyFAERS: 5US FAERS
4Drug ineffective for unapproved indicationFAERS: 5US FAERS
5HeadacheFAERS: 5US FAERS
6NervousnessFAERS: 5US FAERS
7Pharmaceutical product complaintFAERS: 5US FAERS
8Product substitution issueFAERS: 5US FAERS
9PruritusFAERS: 5US FAERS
10SomnolenceFAERS: 5US FAERS
11Drug exposure during pregnancyFAERS: 4US FAERS
12Feeling abnormalFAERS: 4US FAERS
13Feeling jitteryFAERS: 4US FAERS
14NauseaFAERS: 4US FAERS
15FatigueFAERS: 3US FAERS
16PalpitationsFAERS: 3US FAERS
17Therapeutic response unexpected with drug substitutionFAERS: 3US FAERS
18Drug DependenceFAERS: 2US FAERS
19Drug dose omissionFAERS: 2US FAERS
20Drug level increasedFAERS: 2US FAERS
21Drug withdrawal syndromeFAERS: 2US FAERS
22MalaiseFAERS: 2US FAERS
23Pulmonary congestionFAERS: 2US FAERS
24Reaction to drug excipientsFAERS: 2US FAERS
25SinusitisFAERS: 2US FAERS
26TinnitusFAERS: 2US FAERS
27TremorFAERS: 2US FAERS
28Abdominal discomfortFAERS: 1US FAERS
29AnorexiaFAERS: 1623072CTD
US FAERS
30ArthralgiaFAERS: 1US FAERS
31AstheniaFAERS: 1US FAERS
32AsthmaFAERS: 1US FAERS
33Burning sensationFAERS: 1US FAERS
34Chest PainFAERS: 1US FAERS
35ConstipationFAERS: 1US FAERS
36Drug screen false positiveFAERS: 1US FAERS
37Economic problemFAERS: 1US FAERS
38Euphoric moodFAERS: 1US FAERS
39Expired product administeredFAERS: 1US FAERS
40FlushingFAERS: 1US FAERS
41Head discomfortFAERS: 1US FAERS
42HypersensitivityFAERS: 1US FAERS
43Inability to afford medicationFAERS: 1US FAERS
44Intentional product misuseFAERS: 1US FAERS
45Medication ErrorFAERS: 1US FAERS
46Mood swingsFAERS: 1US FAERS
47Neonatal respiratory arrestFAERS: 1US FAERS
48No adverse eventFAERS: 1US FAERS
49OverdoseFAERS: 1US FAERS
50Personality ChangeFAERS: 1US FAERS
51Product formulation issueFAERS: 1US FAERS
52Product quality issueFAERS: 1US FAERS
53Product use complaintFAERS: 1US FAERS
54Quality of life decreasedFAERS: 1US FAERS
55Reaction to excipientFAERS: 1US FAERS
56TachycardiaFAERS: 1US FAERS
57Therapy cessationFAERS: 1US FAERS
58ToothacheFAERS: 1US FAERS
59TrichotillomaniaFAERS: 1US FAERS
60Unevaluable eventFAERS: 1US FAERS
61Visual ImpairmentFAERS: 1US FAERS
62Weight decreasedFAERS: 1US FAERS
63prostatitisFAERS: 1US FAERS
64Amnesia, Anterograde14604717CTD
65Depressive disorder2870641
6130065		CTD
66Erectile dysfunction2870641CTD
67Lethargy6130065CTD
68Necrosis35109CTD
69Nephrotic Syndrome623072CTD
70Proteinuria623072CTD
71Seizures7775702CTD
72Sleep Initiation and Maintenance Disorders7150382CTD
73Substance Withdrawal Syndrome2730383CTD
74Sweat Gland Diseases35109CTD
75Thrombocytopenia623072CTD
76Vomiting623072CTD
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.